



TEJNAKSH HEALTHCARE LIMITED

Regd. Add. : Lion Tarachand Bapa Hospital, Lion Tarachand Bapa Hospital Marg, Sion (W), Mumbai - 22

CIN : L85100MH2008PLC179034, Email : instituteofurology@gmail.com

Website : www.tejnaksh.com | Tel No. : 022 - 2404 4983/ 2404 4984

13.02.2021

To,

BSE Limited

PhirozeJeejeebhoy Towers,

Dalal Street,

Mumbai - 400 001

Dear Sir/Madam,

Scrip Code: 539428

Sub: Submission of Un-Audited Financial Results (Standalone & Consolidated) for the Quarter ended on 31st December, 2020

Please find the enclosed herewith Unaudited Financial Results (Standalone & Consolidated) for the Quarter ended on 31st December, 2020 along with Limited Review Report thereon approved by the Board of Directors of the Company at its Meeting held on Saturday, 13th February, 2021 at Lion Tarachand Bapa Hospital, Lion Tarachand Bapa Hospital Marg, Sion - West, Mumbai - 400 022 at 01.00 p.m., in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is for your information and record.

Thanking you.

For Tejnaksh Healthcare Limited

Dr. Ashish V. Rawandale
Managing Director
DIN:- 02005733



Independent Auditor's Review Report on quarterly and year to date unaudited Standalone Ind AS Financial Results pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

**Review Report to
The Board of Directors
Tejnaksh Healthcare Limited**

1. We have reviewed the accompanying statement of standalone unaudited financial results of Tejnaksh Healthcare Limited ("the Company") for the quarter ended December 31, 2020 and year to date from April 01, 2020 to December 31, 2020 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



5.Emphasis of Matter

We draw attention to Note 4 of the Statement, which describes the circumstances arising due to COVID-19, the uncertainties associated with its nature and duration and the consequential impact of the same on the financial results of the company.

Our conclusion on the statement is not modified in respect or the above matter.

For P.D.Dalal & Co.

Chartered Accountants

ICAI Firm Registration No.102047W

Aashish S. Kakaria

(Aashish S. Kakaria)

Partner

Membership No.102915

UDIN : 21102915AAAACC4787



Mumbai

13th February, 2021



TEJNAKSH HEALTHCARE LIMITED

Regd. Add. : Lion Tarachand Bapa Hospital, Lion Tarachand Bapa Hospital Marg, Sion (W), Mumbai - 22

CIN : L85100MH2008PLC179034, Email : instituteofurology@gmail.com

Website : www.tejnaksh.com | Tel No. : 022 - 2404 4983/ 2404 4984

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER / NINE MONTH ENDED DECEMBER, 2020

Sr.No.	Particulars	Quarter Ended (Rs in 'Lakhs)			Nine Month Ended (Rs in 'Lakhs)		Year Ended
		December 31, 2020	September 30, 2020	December 31, 2019	December 31, 2020	December 31, 2019	March 31, 2020
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	REVENUE						
(a)	Revenue from operations (net)	249.86	263.45	289.06	637.15	881.32	1,113.77
(b)	Other income	0.86	0.98	21.94	4.29	62.28	84.38
	Total Revenue (I)	250.72	264.43	311.00	641.44	943.60	1,198.15
2	EXPENSES						
(a)	Purchases of stock-in-trade	7.64	12.15	15.26	26.69	45.43	53.04
(b)	Changes in inventories of Stock-in-Trade	3.64	(8.14)	(0.53)	(7.54)	(1.25)	12.85
(c)	Employee benefits expense	27.66	26.69	36.19	71.67	118.98	163.80
(d)	Finance costs	12.09	15.31	17.53	41.63	55.02	79.52
(e)	Depreciation and amortization expense	15.85	15.39	15.20	46.54	43.19	58.59
(f)	Other expenses	116.10	113.04	148.83	283.44	419.25	564.28
	Total Expenses (II)	182.98	174.44	232.47	462.43	680.61	932.09
3	Profit before tax (I) - (II)	67.75	89.99	78.53	179.01	262.99	266.06
4	Tax expense:						
(a)	Current tax	11.55	22.16	17.25	36.62	57.05	61.38
(b)	Adjustment of tax relating to earlier periods	-	-	-	-	-	-
(c)	Deferred tax	(4.41)	2.88	4.72	1.48	5.85	12.32
	Total Tax Expenses	7.14	25.03	21.97	38.10	62.90	73.71
5	Profit for the Period	60.61	64.96	56.57	140.91	200.10	192.35
6	OTHER COMPREHENSIVE INCOME						
	A. Other Comprehensive income not to be reclassified to profit and loss in subsequent periods:	-	-	-	-	-	-
	B. Other Comprehensive income to be reclassified to profit and loss in subsequent periods:	-	-	-	-	-	-
	Other Comprehensive income for the year, net of tax	-	-	-	-	-	-
	TOTAL COMPREHENSIVE INCOME FOR THE PERIOD, NET OF TAX	60.61	64.96	56.57	140.91	200.10	192.35
7	Paid up Equity Share Capital (Face value Rs 10/- each.)	101.57	101.57	101.57	101.57	101.57	101.57
8	Basic and Diluted earnings per share (INR)	0.60	0.64	0.56	1.39	1.97	1.89

Notes:

1. The Statement of unaudited standalone financial results ('the Statement') of Tejnaksh Health ('the Company') for the quarter/nine months ended December 31, 2020 has been reviewed by the Audit Risk and Compliance Committee and approved by the Board of Directors on February 13, 2021. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results.

2. The Statement has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim financial Reporting", prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.



TEJNAKSH HEALTHCARE LIMITED

Regd. Add. : Lion Tarachand Bapa Hospital, Lion Tarachand Bapa Hospital Marg, Sion (W), Mumbai - 22

CIN : L85100MH2008PLC179034, Email : instituteofurology@gmail.com

Website : www.tejnaksh.com | Tel No. : 022 - 2404 4983/ 2404 4984

3. The Company's operating segment is 'Medical and Healthcare Services. Since the Company has a single operating segment, disclosure pertaining to segments as per Regulation 33(1)(c) read with clause (L) of Part A of Schedule IV of the SEBI Regulations is not applicable.


4. The outbreak of corona virus (COVID-19) pandemic globally and in India is causing significant disturbance and slowdown of economic activity. The Company's operations and revenue during the period were impacted due to COVID-19. The Company has taken into account the possible impact of COVID-19 in preparation of the unaudited standalone financial results, including its assessment of recoverable value of its assets based on internal and external information upto the date of approval of these unaudited standalone financial results and current indicators of future economic conditions.

5. The figures for the corresponding previous period have been regrouped / reclassified wherever necessary, to make them comparable.

6. There were no investor complaints received / pending as at 31st December, 2020.

Place: Mumbai
Date: 13.02.2021

For and on behalf of board of Directors
Tejnaksh Healthcare Limited


(Dr. A.V. Rawandale)
Managing Director
DIN: 02005733



Independent Auditor's Limited Review Report on quarterly and year to date unaudited Consolidated Ind AS Financial Results pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

**Review Report to
The Board of Directors
Tejnaksh Healthcare Limited**

1. We have reviewed the accompanying statement of Consolidated Unaudited Financial Results of Tejnaksh Healthcare Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended December 31, 2020 and year to date from April 01, 2020 to December 31, 2020 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parents Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34. (Ind AS 34) 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410. Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. The Statement includes results of the Holding Company- Tejnaksh Healthcare Limited and subsidiary Company - TejVedaant Healthcare Private Limited.

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6.Emphasis of Matter

We draw attention to Note 5 of the Statement, which describes the circumstances arising due to COVID-19, the uncertainties associated with its nature and duration and the consequential impact of the same on the financial results of the Group.

Our conclusion on the Statement is not modified in respect or the above matter.

For P.D.Dalal & Co.

Chartered Accountants

ICAI Firm Registration No.102047W

Aashish

(Aashish S. Kakaria)

Partner

Membership No.102915

UDIN : 21102915AAAACD2976



Mumbai

13th February, 2021



TEJNAKSH HEALTHCARE LIMITED

Regd. Add. : Lion Tarachand Bapa Hospital, Lion Tarachand Bapa Hospital Marg, Sion (W), Mumbai - 22

CIN : L85100MH2008PLC179034, Email : instituteofurology@gmail.com

Website : www.tejnaksh.com | Tel No. : 022 - 2404 4983/ 2404 4984

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER / NINE MONTH ENDED DECEMBER, 2020

Sr.No.	Particulars	Quarter Ended (Rs in 'Lakhs)			Nine Month Ended (Rs in 'Lakhs)		Year Ended
		December 31,2020	September 30,2020	December 31,2019	December 31,2020	December 31,2019	March 31,2020
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	REVENUE						
(a)	Revenue from operations (net)	342.16	334.32	429.32	834.93	1,320.96	1,675.65
(b)	Other income	0.01	0.13	19.14	1.98	54.25	70.11
	Total Revenue (I)	342.17	334.45	448.46	836.91	1,375.21	1,745.76
2	EXPENSES						
(a)	Purchases of stock-in-trade	21.50	24.45	29.85	57.23	94.00	109.75
(b)	Changes in inventories of Stock-in-Trade	6.31	(7.74)	1.66	(6.17)	4.40	19.97
(c)	Employee benefits expense	40.22	36.61	64.76	101.16	188.21	255.42
(d)	Finance costs	11.24	14.45	17.78	39.06	56.31	76.10
(e)	Depreciation and amortization expense	17.56	17.12	16.95	51.69	48.28	65.44
(f)	Other expenses	177.06	169.09	234.70	434.98	694.51	922.51
	Total Expenses (II)	273.89	253.98	365.70	677.95	1,085.72	1,449.20
3	Profit before tax (I) - (II)	68.28	80.47	82.77	158.96	289.48	296.56
4	Tax expense:						
(a)	Current tax	11.55	22.16	18.68	36.62	63.56	69.30
(b)	Adjustment of tax relating to earlier periods	-	-	-	-	-	-
(c)	Deferred tax	(4.75)	2.94	5.00	1.04	6.36	12.69
	Total Tax Expenses	6.80	25.10	23.68	37.66	69.91	81.99
5	Profit for the year	61.48	55.37	59.08	121.30	219.57	214.57
6	OTHER COMPREHENSIVE INCOME						
	A. Other Comprehensive income not to be reclassified to profit and loss in subsequent periods:	-	-	-	-	-	-
	B. Other Comprehensive income to be reclassified to profit and loss in subsequent periods:	-	-	-	-	-	-
	Other Comprehensive income for the year, net of tax	-	-	-	-	-	-
	TOTAL COMPREHENSIVE INCOME FOR THE PERIOD, NET OF TAX	61.48	55.37	59.08	121.30	219.57	214.57
7	Profit for the year attributable to:						
	Equity holders of the parent	61.26	57.76	58.45	126.20	214.70	209.01
	Non-controlling interests	0.22	(2.39)	0.63	(4.90)	4.87	5.55
8	Total comprehensive income for the year attributable to:						
	Equity holders of the parent	61.26	57.76	58.45	126.20	214.70	209.01
	Non-controlling interests	0.22	(2.39)	0.63	(4.90)	4.87	5.55
9	Paid up Equity Share Capital (Face value)	101.57	101.57	101.57	101.57	101.57	101.57
10	Basic and Diluted earnings per share (INR)	0.60	0.57	0.58	1.24	2.11	2.06

Notes:

1. The Statement of unaudited consolidated financial results ('the Statement') of Tejnaksh Health (the 'Parent/ 'Group') and its subsidiaries (together referred to as the 'Group') for the quarter/nine months ended December 31, 2020 has been reviewed by the Audit Risk and Compliance Committee and approved by the Board of Directors on February 13, 2021. The Statutory Auditors of the Group have carried out a Limited Review of the aforesaid results.

2. The consolidated unaudited financial result relates to Tejnaksh Healthcare Limited, the Holding Group and its subsidiary Tejvedaant Healthcare Private Limited.



TEJNAKSH HEALTHCARE LIMITED

Regd. Add. : Lion Tarachand Bapa Hospital, Lion Tarachand Bapa Hospital Marg, Sion (W), Mumbai - 22

CIN : L85100MH2008PLC179034, Email : instituteofurology@gmail.com

Website : www.tejnaksh.com | Tel No. : 022 - 2404 4983/ 2404 4984

3. The Company's operating segment is 'Medical and Healthcare Services. Since the Company has a single operating segment, disclosure pertaining to segments as per Regulation 33(1)(c) read with clause (L) of Part A of Schedule IV of the SEBI Regulations is not applicable.

4. The outbreak of corona virus (COVID-19) pandemic globally and in India is causing significant disturbance and slowdown of economic activity. The Company's operations and revenue during the period were impacted due to COVID-19. The Company has taken into account the possible impact of COVID-19 in preparation of the unaudited standalone financial results, including its assessment of recoverable value of its assets based on internal and external information upto the date of approval of these unaudited standalone financial results and current indicators of future economic conditions.

5. The figures for the corresponding previous period have been regrouped / reclassified wherever necessary, to make them comparable.

6. There were no investor complaints received / pending as at 31st December, 2020.

Place: Mumbai
Date: 13.02.2021

For and on behalf of board of Directors
Tejnaksh Healthcare Limited

(Dr. A.V. Rawandale)
Managing Director
DIN: 02005733

